Therefore, SGLT2i may not control tumor growth through the inhibition of glucose uptake by SGLT2, but through various other pathways to control the growth of breast cancer, but its clinical application needs to be further investigated. This evidence concerns the gene SLC5A2 and breast carcinoma.